滚动资讯
10x Genomics BlogLiquidCell Dx Appoints Former Foundation Medicine, 10x Genomics and IDT Leader Mirna Jarosz as Chief Executive Officer; Names Former Foundation Medicine Chief Medical Officer Vincent A. Miller, MD, Senior Strategic Advisor - BioSpaceThermo FisherThermo Fisher Scientific: Why A Slow Q1 Does Not Reflect The Growth Opportunities - Seeking AlphaMOONS'阿尔忒弥斯计划将如何助美国打造月球基地AgilentAgilent Technologies Inc (A) Shares Fall 5.0% -- What GF Score o - GuruFocusThermo FisherThermo Fisher Scientific Inc. stock falls Thursday, underperforms market - MarketWatchFierceBiotech尽管存在数据隐忧，罗氏口服SERD仍有望成为公司史上最大产品：高管FierceBiotechRegeneron ushers in new genetic medicine era with groundbreaking gene therapy approvalThermo FisherThermo Fisher CEO says onshoring push will bring a ‘tailwind’ for the Waltham company - The Business Journals10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - StockStoryAgilentEarnings snapshot: Agilent Technologies misses FQ1 estimates; gives FQ2 and raises FY26 outlook, above forecast - MSNThermo FisherThermo Fisher Scientific Inc. Q1 2026 Earnings Call Summary - Yahoo Finance10x Genomics BlogWhy 10x Genomics (TXG) Shares Are Trading Lower Today - TradingView
Endpoints News 2026年1月6日

礼来以5500万美元协议重返Nimbus，寻求口服肥胖症药物。

礼来以5500万美元协议重返Nimbus，寻求口服肥胖症药物。

原文
暂时没有全文，请查看原始来源。